Business
Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10
TORRANCE, Calif.--(BUSINESS WIRE)-- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today
About this update from Forte Biosciences, Inc.
[{"type":"text","content":" TORRANCE, Calif.--(BUSINESS WIRE)--\nForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that it will release second quarter 2020 results after the market close on Monday, August 10, 2020 and host a conference call at 4:30 p.m. ET to discuss second quarter 2020 results as well as to provide a general business update.\n\n\nDial-in Number \n\n\nU.S. Dial-In: 877-300-8521\nInt’l Dial-In: 412-317-6026\n\n\nPasscode: 10147071\n\n\nWebcast\nhttp://public.viavid.com/index.php?id=141126\n\n\nA live webcast of the call will also be available online in the investor relations section of Forte’s website at https://www.fortebiorx.com/ and will be archived there until August 17, 2020.\n\n\nAbout Forte\n\n\nForte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. There is a significant unmet need for safe and effective therapies particularly for pediatric atopic dermatitis patients. Forte plans to advance FB-401 into a randomized Phase 2 clinical trial in mid-2020.\n\n\nSource: Forte Biosciences, Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200803005134/en/\n\nForte Biosciences, Inc.\nPaul Wagner, CEO\[email protected]\n\nSource: Forte Biosciences, Inc.","length":4434,"tagName":"div"}]